Series A19 January 2022

Engitix secures £40m Series A funding to advance its drug discovery pipeline

The financing round was co-led by Netherton Investments and Dompé farmaceutici.

£40.0MSeries A

Engitix is a biotechnology company focused on extracellular matrix targets to develop therapies for cancer and fibrosis. It operates from London and maintains partnerships with major pharmaceutical firms.

Engitix has raised £40m in a Series A financing round co-led by Netherton Investments and Dompé farmaceutici. The funding will allow the biopharmaceutical company to advance its internal drug discovery pipeline, expand its platform capabilities, and grow its team and operations. Alongside the financing, Engitix secured a multi-year strategic collaboration with Dompé to leverage supercomputing power for drug discovery.

From the founder

"We are pleased to have the continued backing of Mike Platt, and to have secured the support of Dompé as a partner and investor."

Giuseppe Mazza

CEO at Engitix

Investor perspective

"Our mission is to improve people’s lives and we partner with the best academic and industrial groups to accelerate the research that will bring new solutions to patients’ unmet needs. We look forward to working with the Engitix team to combine the power of Exscalate with Engitix’s deep understanding of the biology of the fibrosis and solid tumours microenvironment and the unique strength of its ECM platform. Our collaboration will enable us to accelerate the clinical translation of targets beyond our four key in-house therapeutic areas of ophthalmology, metabolic disorders, oncology, and pain management."

Marcello Allegretti

CSO, Dompé farmaceutici